Introduction: After more than 20 years of sustained work, the Latin American Group for the Study of Lupus (GLADEL) has made a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region. Methods: A new generation of “Lupus Investigators” in more than 40 centers throughout Latin America has been constituted in order to continue the legacy of the investigators of the original cohort and to launch a novel study of serum and urinary biomarkers in patients with systemic lupus erythematosus. Results: So far, we have recruited 807 patients and 631 controls from 42 Latin-American centers including 339 patients with SLE without renal involvement, 202 patients with SLE with prevalent but inactive renal disease, 176 patients with prevalent and active renal disease and 90 patients with incident lupus nephritis. Conclusions: The different methodological aspects of the GLADEL 2.0 cohort are discussed in this manuscript, including the challenges and difficulties of conducting such an ambitious project.
Pons-EstelBACatoggioLJCardielMH, et al.
The GLADEL multinational latin american prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “hispanics”. Medicine (Baltimore)2004;
83: 1–17.
2.
Pons-EstelGJCatoggioLJCardielMH, et al.
Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus2015;
24: 536–545.
3.
Alarcón-SegoviaDAlarcón-RiquelmeMECardielMH, et al.
Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis and/or other autoimmune diseases in 1177 lupus patients from the GLADEL cohort. Arthritis Rheum2005;
52: 1138–1147.
4.
GarcíaMAMarcosJCMarcosAI, et al.
Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus2005;
14: 938–946.
5.
Ramírez GómezLUribe UribeOOsio UribeO, et al.
Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus.Lupus2008;
17: 596–604.
6.
CatoggioLJSorianoERImamuraPM, et al.
Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?Lupus2015;
24: 788–795.
7.
Ugarte-GilMFWojdylaDPastor-AsurzaCA, et al.
Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus2018;
27: 536–544.
8.
Pimentel-QuirozVRUgarte-GilMFPons-EstelGJ, et al.
Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Semin Arthritis Rheum2017;
47: 199–203.
9.
Pons-EstelGJAlarcónGSHachuelL, et al.
Antimalarials exert a protective effect while mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford)2012;
51: 1293–1298.
10.
Pons-EstelGJAlarcónGSBurgosPI, et al.
Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus2013;
22: 899–907.
11.
GarcíaMAAlarcónGSBoggioG, et al.
Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors – data from a multi-ethnic Latin American cohort. Rheumatology (Oxford)2014;
53: 1431–1438.
12.
González-NaranjoLABetancurOMAlarcónGS, et al.
Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: data from a multiethnic Latin American cohort. Semin Arthritis Rheum2016;
45: 675–683.
13.
Pimentel-QuirozVRUgarte-GilMFHarveyGB, et al.
Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national. Latin American lupus cohort. Lupus2019;
28: 1101–1110.
14.
ShinjoSKBonfáEWojdylaD, et al.
Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum2010;
62: 855–862.
15.
Ugarte-GilMFWojdylaDPons-EstelGJ, et al.
Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis2017;
76: 2071–2074.
16.
Ugarte-GilMFWojdylaDPons-EstelGJ, et al.
Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multi-ethnic, multinational Latin-American lupus cohort. J Rheumatol2019;
46: 1299–1308.
17.
CardielMHSorianoERBonfáE, et al.
Therapeutic guidelines for Latin American lupus patients: methodology. J Clin Rheumatol2018;
24: 41–44.
18.
Pons-EstelBABonfaESorianoER, et al.
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American league of associations of rheumatology (PANLAR). Ann Rheum Dis2018;
77: 1549–1557.
19.
MokCC.Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol2010;
2010: 638413.
AragónCCPosso-OsorioIPuertaG, et al.
Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases. Clin Rheumatol2020;
39: 2163–2169.
22.
Ardila-SuarezOGómez-PuertaJAKhamashtaMA.Diagnosis of antiphospholipid syndrome: from an historical perspective to the emergence of new autoantibodies. Med Clin (Barc)2016;
146: 555–560.
23.
BiggioggeroMMeroniPL.The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev2010;
9: A299–A304.
24.
RovinBHSongHBirminghamDJ, et al.
Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol2005;
16: 467–473.
25.
González-SánchezDAÁlvarezCMVásquezGGómez-PuertaJA.Role of TWEAK/Fn14 signalling pathway in lupus nephritis and other clinical settings. Nefrologia2017;
37: 118–125.
26.
GuptaRAggarwalASinhaS, et al.
Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity. Lupus2016;
25: 1230–1236.
27.
Gómez-PuertaJAOrtiz-ReyesBUrregoT, et al.
Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients. Lupus2018;
27: 637–646.
28.
UrregoTOrtiz-ReyesBVanegas-GarcíaAL, et al.
Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. Reumatol Clin2020;
16: 17–23.
29.
Reyes-MartínezFPérez-NavarroMRodríguez-MatíasA, et al.
Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: an exploratory study. Nefrologia2018;
38: 152–160.
30.
UrregoTOrtiz-ReyesBArocaG, et al.
Urinary levels of VCAM-1 and TWEAK as biomarkers of lupus nephritis. Ann Rheum Dis2017;
76: 1239 (Abstract).
31.
Gómez-PuertaJAUrregoTReyes BO, et al.
Prognostic value of urinary biomarkers for the developing of end stage renal disease in patients with systemic lupus erythematosus (Abstract). Arthritis Rheumatol2019;
71.
32.
TanEMCohenASFriesJF, et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982;
25: 1271–1277.
33.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
34.
PetriMOrbaiA-MAlarcónGS, et al.
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
35.
AringerMCostenbaderKDaikhD, et al.
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019;
78: 1151–1159.
GladmanDDGinzlerEGoldsmithCh, et al.
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum1996;
39: 363–369.
38.
McElhoneKAbbottJShelmerdineJ, et al.
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum2007;
57: 972–979.
39.
ReillyMCZbrozekASDukesEM.The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics1993;
4: 353–365.
40.
Pons-EstelBVillalbaDAlvarellosA, et al.
ARTHROS 2.0: a rheumatology database (abstract). Ann Rheum Dis1999;
58: 153.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
